← Back to Search

JSP191 for Myelodysplastic Syndrome

Phase 1

Recruiting

Research Sponsored by Jasper Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 32 weeks

Awards & highlights

Study Summary

This trial tests if a new drug is safe and works for a certain type of blood cancer.

Who is the study for?

This trial is for adults over 18 with low to intermediate-risk Myelodysplastic Syndrome (MDS) who have symptoms like anemia or bleeding. Women able to have children must use effective birth control, and men too, during the study and for 3 months after. Participants need to understand and agree to the study's requirements.Check my eligibility

What is being tested?

The trial is testing JSP191 (Briquilimab) as a second-line treatment for MDS. It's in Phase 1, which means it's early in testing and focuses on how safe it is and what doses are tolerable when given to people.See study design

What are the potential side effects?

Since this is a Phase 1 trial primarily assessing safety, specific side effects of JSP191 aren't listed but may include typical drug reactions such as nausea, fatigue, allergic responses or more serious effects depending on individual patient response.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 32 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~32 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 32 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety and tolerability of JSP191

Trial Design

1Treatment groups

Experimental Treatment

Group I: JSP191Experimental Treatment1 Intervention

This study will explore up to 5 ascending dose levels (Cohorts 1, 2, 3, 4, and 5) and subjects will receive JSP191 on Day 1 on each 8-week cycle for 4 consecutive cycles.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Jasper Therapeutics, Inc.Lead Sponsor

4 Previous Clinical Trials

142 Total Patients Enrolled

David HindsStudy DirectorJasper Therapeutics, Inc.

1 Previous Clinical Trials

Media Library

JSP191 Clinical Trial Eligibility Overview. Trial Name: NCT05903274 — Phase 1

Myelodysplastic Syndrome Research Study Groups: JSP191

Myelodysplastic Syndrome Clinical Trial 2023: JSP191 Highlights & Side Effects. Trial Name: NCT05903274 — Phase 1

JSP191 2023 Treatment Timeline for Medical Study. Trial Name: NCT05903274 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has JSP191 obtained regulatory authorization from the FDA?

"We have ranked JSP191 a 1 on the safety scale, as this is only a Phase 1 trial. This signifies that there is still limited information regarding its efficacy and risk profile."

Answered by AI

What is the upper limit for participant enrollment in this research endeavor?

"Affirmative. The information located on clinicaltrials.gov suggests that this medical study, which was initially announced on June 1st 2023, is currently recruiting patients. There are 30 vacancies at a single site available for the trial."

Answered by AI

Is enrollment for this experiment open at the current moment?

"Yes, according to the clinicaltrials.gov website, this research initiative is actively seeking participants. It was first published on June 1st 2023 and has been updated most recently on June 5th of that same year. 30 individuals are being sought out across a single site for participation in this study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

JSP191 (Briquilimab) in Subjects With LR-MDS

2023. "JSP191 (Briquilimab) in Subjects With LR-MDS". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05903274.